Protovir®, MSL 109, EV2 7, SDZ MSL 109
Section 1: Cytomegalovirus Retiniti Adis R&D Profile
KeywordsAdis International Limited Ganciclovir Retinitis Foscarnet Undergo Bone Marrow Transplan
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 2.Nokta MA, Tolpin MD, Nadler PI, et al. Human monoclonal anti cytomegalovirus antibody (MSL-109): enhancement of in vitro ganciclovir induced inhibition of CMV replication. Antiviral Res 1991 Apr; 15 Suppl. 1: 77Google Scholar
- 3.Protein Design Labs announces results from phase II study of PROTOVIR (Rm) in bone marrow transplantation. PR Newswire [online]. 2 Jul 1997. URL: http://www.newspage.com [Accessed 1997 Jul 14]
- 4.Dunkel EC, Siegel ML, Brooks J, et al. MSL-109 therapy of human cytomegalovirus-induced chorioretinitis in the rabbit. Antiviral Res 1991 Apr; 15 Suppl. 1: 121Google Scholar
- 6.Nokta M, Tolpin M, Nadler P, et al. Combination effects of a human monoclonal anti cytomegalovirus (CMV) antibody (MSL 109) and foscarnet or ganciclovir on CMV replication in vitro. Antiviral Res 1993; 20 Suppl. 1: 110Google Scholar
- 7.Tolpin M, Pollard R, Tierney M, et al. Combination therapy of cytomegalovirus retinitis with a human monoclonal anti-CMV antibody (SDZ MSL 109) and either ganciclovir or foscarnet. 9th International Conference on AIDS; 1993 Jun 6–11; Berlin, I: 54Google Scholar
- 8.Protein Design Labs announces halt to one of three ongoing clinical trials in CMV disease [media release]. PR Newswire 1996 Aug 14Google Scholar
© Adis International Limited 1999